Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Evelo Biosciences Inc (NQ: EVLO )

10.84 USD -0.71 (-6.15%)
Official Closing Price Updated: 5:16 PM EDT, Apr 20, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Evelo Biosciences Inc

< Previous 1 2 3 Next >
Evelo Biosciences Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815 in Atopic Dermatitis
From GlobeNewswire News Releases
Evelo Biosciences Announces Appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to the Board of Directors
From GlobeNewswire News Releases
Thinking about buying stock in Nuance Communications, GameStop, Evelo Biosciences, Progenity, or Fortress Biotech?
InvestorsObserver issues critical PriceWatch Alerts for NUAN, GME, EVLO, PROG, and FBIO. 
From PR Newswire
Tessera Therapeutics Strengthens Leadership Team to Advance ‘Gene Writing’ Platform & Accelerate Therapeutic Development
Tessera Therapeutics, a biotech company pioneering Gene Writing, announced today the appointment of David Davidson, M.D. as Chief Medical and Development Officer, Hari Pujar, Ph.D. as Chief Operating... 
From Business Wire News Releases
Evelo Biosciences to Present at 20th Annual Needham Virtual Healthcare Conference
From GlobeNewswire News Releases
Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer
Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental... 
From PR Newswire
Evelo Biosciences & Abdul Latif Jameel Health Announce Strategic Collaboration to Develop & Commercialize Novel Therapy EDP1815 for Inflammatory Diseases & COVID-19 in Select Developing Markets Servin
From GlobeNewswire News Releases
Evelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
From GlobeNewswire News Releases
Evelo Biosciences to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 9, 2021
From GlobeNewswire News Releases
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target
Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it raised $123 million in Series B financing. The... 
From PR Newswire
Evelo Biosciences Appoints John A. Hohneker, M.D. to Board of Directors
From GlobeNewswire News Releases
Evelo Biosciences Announces Pricing of Public Offering of Common Stock
From GlobeNewswire News Releases
Evelo Biosciences Announces Proposed Public Offering of Common Stock
From GlobeNewswire News Releases
Evelo Biosciences Reports New Positive Confirmatory Data from Phase 1b Trial of EDP1815 in Atopic Dermatitis
From GlobeNewswire News Releases
Evelo Biosciences Expands Clinical Programs and Provides 2021 Guidance on Key Milestones
From GlobeNewswire News Releases
Evelo Biosciences Appoints Industry Veteran Jonathan Zung, Ph.D. as Chief Development Officer
From GlobeNewswire News Releases
Thinking about buying stock in OncoCyte, FuelCell Energy, Evelo Biosciences, Lydall, or Prevail Therapeutics?
InvestorsObserver issues critical PriceWatch Alerts for OCX, FCEL, EVLO, LDL, and PRVL. 
From PR Newswire
Why Transdermal Drug Delivery Systems are Outweighing Advantages of Traditional Methods
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Why Transdermal Drug Delivery Systems are Outweighing Advantages of Traditional Methods
Financialnewsmedia.com News Commentary 
From PR Newswire
Evelo Biosciences Announces New Clinical Candidate in Oncology and Presents Additional Interim Data from Phase 1/2 Clinical Trial of EDP1503 in Patients with Triple-Negative Breast Cancer
From GlobeNewswire News Releases
Evelo Biosciences Reports Positive Topline Clinical Data in Phase 1b Trial of EDP1815 in Atopic Dermatitis
From GlobeNewswire News Releases
Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of Psoriasis
From GlobeNewswire News Releases
Evelo Biosciences Presents New Preclinical Data for Anti-Tumor Effects of Orally Delivered Microbial Extracellular Vesicles at the SITC 35th Anniversary Annual Meeting
From GlobeNewswire News Releases
Evelo Biosciences Reports Third Quarter 2020 Financial Results and Business Highlights
From GlobeNewswire News Releases
Evelo Biosciences to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020
From GlobeNewswire News Releases
Evelo Biosciences to Host Key Opinion Leader Discussion Focused on the Unmet Need in Psoriasis and Atopic Dermatitis and the Potential Opportunity for EDP1815
From GlobeNewswire News Releases
Evelo Biosciences Completes Enrollment in Phase 1b Clinical Trial Cohort Evaluating EDP1815 in Atopic Dermatitis
–Data expected in 1Q 2021– 
From GlobeNewswire News Releases
Evelo Biosciences Treats First Patients in Phase 2 Dose-Ranging Trial of EDP1815 for the Treatment of Psoriasis
From GlobeNewswire News Releases
Evelo Biosciences Appoints Julie Carretero as Chief People Officer
From GlobeNewswire News Releases
Evelo Biosciences to Participate in Upcoming Investor Conferences in September
From GlobeNewswire News Releases
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.